MedTrace Logo

Efficacy of Varenicline in Ambivalent Smokers

NCT00595868 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2011-12-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether Varenicline can help ambivalent smokers (those who are interested in quitting at some point in the future but have no current plans to quit) to reduce their smoking and eventually quit.

Conditions

  • Tobacco Use Disorder
  • Tobacco Use Cessation
  • Nicotine Dependence

Interventions

DRUG

Varenicline

0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months

DRUG

Placebo

same as Varenicline arm

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Vermont Medical Center

    lead OTHER

Principal Investigators

  • John R Hughes, MD · University of Vermont

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595868 on ClinicalTrials.gov